Access count of this item: 192

Files in This Item:
File Description SizeFormat 
34_528.pdf2.5 MBAdobe PDFView/Open
Title: 尿路性器癌の骨転移症例に対するDisodium (EHDP)Etidronateの効果検討
Other Titles: Effects of etidronate disodium (EHDP) on urogenital malignancies with bone metastasis: a multicentered collaborative evaluation
Authors: 川村, 寿一  KAKEN_name
栃木, 宏水  KAKEN_name
柳川, 真  KAKEN_name
吉田, 修  KAKEN_name
飛田, 収一  KAKEN_name
森, 脩  KAKEN_name
鈴木, 紀元  KAKEN_name
斉藤, 薫  KAKEN_name
小松, 洋輔  KAKEN_name
畑山, 忠  KAKEN_name
中川, 清秀  KAKEN_name
Author's alias: KAWAMURA, Juichi
TOCHIGI, Hiromi
YANAGAWA, Makoto
YOSHIDA, Osamu
HIDA, Shuichi
MORI, Osamu
SUZUKI, Norimoto
SAITO, Kaoru
KOMATSU, Yosuke
HATAYAMA, Tadashi
NAKAGAWA, Kiyohide
Keywords: EHDP
Urogenital malignancies
Bone metastasis
Bone pain
Issue Date: Mar-1988
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 34
Issue: 3
Start page: 528
End page: 537
Abstract: Clinical effects of EHDP on relief of bone pain, changes in bone lesions on X-ray and 99mTc-MDP scintigram and performance status were investigated in 19 patients with bone metastasis from urogenital cancers (4 renal cell cancers, 1 renal pelvic cancer, 4 bladder cancers and 10 prostatic cancers). EHDP was effective in relieving bone pain in prostatic cancer patients with osteoblastic lesions. Bone lesions on X-ray and 99mTc-MDP scintigram were slightly improved in prostatic cancer patients with osteoblastic lesions. Administration of EHDP did not improve the performance status. Changes in laboratory data such as serum alkaline phosphatase, serum calcium and urinary total hydroxy-proline following EHDP administration indicated inhibition of osteolytic activity with no effect on bone formation in the early period of treatment (in 4 weeks) and development of both osteolytic activity and bone formation in the later period (from 8 to 12 weeks). No marked side effects were observed. EHDP seems to be effective in relieving bone pain in prostatic cancer patients with osteoblastic bone metastasis. Moreover, some diphosphonate groups including EHDP are expected to be useful to the patients with malignant hypercalcemia.
URI: http://hdl.handle.net/2433/119491
PubMed ID: 3133934
Appears in Collections:Vol.34 No.3

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.